Saturday 17 October 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
45.97
1.28
−2.71%
Follow RIGL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.52 | 2.12 |
Piotroski F-Score |
1 | 3 | 4 | 3 | 4 | 7 | 1 | 4 | 7 | 6 |
Altman Z-Score |
(15.04) | 1.37 | (5.05) | (10.46) | (11.28) | (7.80) | (13.39) | (14.88) | (8.66) | 2.71 |
P/S ratio |
11.53 | 44.49 | 8.13 | 6.04 | 5.44 | 3.03 | 1.90 | 2.17 | 1.65 | 2.62 |
Altman Z″-Score (non-manufacturers) |
(43.26) | (24.48) | (22.75) | (28.03) | (37.01) | (22.50) | (33.96) | (37.95) | (23.75) | 0.31 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.04 | 0.00 | 0.00 | 9.45 | 10.21 |
Beneish M-Score |
— | — | — | 10.69 | (1.18) | (3.35) | 0.06 | (3.48) | (2.31) | 0.78 |
P/Operating CF |
(18.86) | (25.37) | 31.71 | (37.13) | (37.93) | (23.67) | (10.43) | (40.71) | 20.39 | 35.05 |
P/B ratio |
4.27 | 4.97 | 3.36 | 6.66 | 17.36 | 14.87 | 0.00 | 0.00 | 89.93 | 1.97 |
Price to Tangible BV |
4.27 | 4.97 | 3.36 | 6.66 | 17.36 | 14.87 | 0.00 | 0.00 | 0.00 | 2.10 |
EV/Sales |
7.87 | 34.22 | 5.31 | 4.55 | 5.09 | 2.32 | 1.74 | 2.13 | 1.51 | 2.17 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.53 | 5.03 |
EV/Operating CF |
(2.11) | (4.96) | (4.10) | (6.50) | (10.60) | 58.99 | (2.84) | (43.44) | 8.60 | 8.43 |
EV/FCF |
(2.10) | (5.00) | (4.02) | (6.28) | (10.35) | 66.04 | (2.86) | (12.18) | 8.65 | 8.45 |
Quick Ratio |
3.31 | 6.31 | 4.78 | 1.86 | 1.79 | 2.21 | 1.51 | 1.64 | 1.88 | 2.08 |
Current Ratio |
3.37 | 6.40 | 4.94 | 2.04 | 2.18 | 2.43 | 1.78 | 1.86 | 2.13 | 2.42 |
Net Debt/EBITDA |
1.09 | 1.46 | 1.76 | 1.27 | 1.32 | 9.51 | 0.34 | 0.23 | (0.97) | (1.05) |
Debt/Assets |
0.30% | 0.00% | 0.00% | 6.65% | 17.95% | 11.90% | 29.38% | 44.68% | 31.96% | 4.38% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.18 | 0.58 | 0.66 | (2.90) | (1.83) | 15.94 | 0.06 |
Asset Turnover |
0.19 | 0.05 | 0.34 | 0.41 | 0.84 | 1.07 | 0.80 | 0.93 | 1.28 | 0.87 |
Operating CF/Net income |
1.10 | 0.99 | 0.83 | 0.62 | 1.75 | (0.33) | 1.26 | 0.23 | 1.80 | 0.21 |
Capex/Depreciation |
(0.68) | 4.94 | 6.43 | 3.73 | (2.16) | (0.43) | 0.47 | (19.42) | (0.20) | 0.00 |
Interest Coverage |
(159.59) | — | — | (206.24) | (21.41) | (2.57) | (14.99) | (2.98) | 3.06 | 17.14 |
| (94.55%) | (100.20%) | (66.96%) | (81.73%) | (67.72%) | (55.63%) | (699.05%) | 118.75% | (137.92%) | 185.94% | |
| (65.96%) | (79.08%) | (54.59%) | (46.67%) | (23.06%) | (12.90%) | (38.84%) | (19.95%) | 12.44% | 108.34% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 30.28% |
Return on Tangible Assets |
(126.35%) | (78.01%) | (63.70%) | (106.26%) | (58.53%) | (19.24%) | (113.63%) | (54.35%) | 24.32% | 260.43% |
Average Days of Receivables |
0.00 | 0.00 | 33.43 | 62.25 | 53.67 | 37.84 | 122.39 | 95.40 | 84.73 | 64.20 |
Research and Development Expense of Revenue |
311.27% | 1,031.87% | 105.38% | 89.20% | 55.33% | 43.71% | 50.13% | 20.98% | 13.04% | 11.31% |
Selling, General and Administrative Expense of Revenue |
102.58% | 843.69% | 157.28% | 125.81% | 70.52% | 61.57% | 93.52% | 90.47% | 63.06% | 39.38% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.12 | 0.17 | 0.05 |
Share Based Compensation of Revenue |
35.98% | 133.52% | 17.31% | 15.37% | 6.72% | 6.36% | 10.30% | 7.53% | 6.91% | 4.32% |
Graham Net Nets |
0.23 | 0.20 | 0.29 | 0.07 | 0.02 | 0.04 | (0.14) | (0.18) | (0.09) | 0.15 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.82 | 7.34 | 2.01 | 99.56 |
Earnings Yield |
(29.72%) | (15.40%) | (19.57%) | (18.69%) | (4.57%) | (3.77%) | (25.37%) | (9.97%) | 5.71% | 47.26% |
Free Cash Flow Yield |
(32.59%) | (15.39%) | (16.23%) | (11.99%) | (9.05%) | 1.16% | (32.09%) | (8.06%) | 10.59% | 9.79% |
Revenue per Share |
2.16 | 0.36 | 2.77 | 3.54 | 6.44 | 8.75 | 7.05 | 6.72 | 10.20 | 16.36 |
Operating CF per Share |
(8.04) | (6.14) | (3.66) | (2.48) | (3.09) | 0.34 | (4.33) | (0.33) | 1.79 | 4.21 |
Capex per Share |
(0.08) | 0.05 | (0.07) | (0.09) | (0.07) | (0.04) | 0.03 | (0.85) | (0.02) | 0.00 |
Free Cash Flow per Share |
(8.12) | (6.09) | (3.73) | (2.57) | (3.17) | 0.31 | (4.30) | (1.18) | 1.77 | 4.21 |
Cash per Share |
7.92 | 9.16 | 8.01 | 5.86 | 3.40 | 7.33 | 3.41 | 3.27 | 4.40 | 8.61 |
Shareholders Equity per Share |
5.83 | 7.97 | 6.84 | 3.21 | 2.02 | 1.78 | (0.80) | (1.65) | 0.19 | 21.76 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.83 | 7.97 | 6.84 | 3.21 | 2.02 | 1.78 | (0.80) | (1.65) | 0.19 | 21.76 |
Free Cash Flow |
(76.60) | (76.99) | (59.93) | (42.96) | (53.45) | 5.25 | (73.31) | (20.48) | 31.17 | 75.66 |
Working Capital |
53.63 | 99.10 | 109.25 | 60.79 | 48.14 | 90.91 | 50.69 | 46.00 | 71.80 | 140.93 |
Capital Expenditures |
(0.72) | 0.57 | (1.11) | (1.45) | (1.26) | (0.63) | 0.44 | (14.74) | (0.30) | — |
Net Current Asset Value |
53.11 | 98.97 | 107.76 | 25.25 | 12.63 | 17.51 | (31.99) | (46.60) | (25.58) | 118.05 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.19 | 5.08 |
Capex to Sales |
0.04 | (0.13) | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.22 | 6.14 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.91 | 0.13 | (0.12) | (0.18) | 0.22 | 0.66 | 1.09 | 4.60 | 16.51 | 0.00 |
Cash ROIC |
(58.91%) | (35.58%) | (25.14%) | (26.57%) | (48.08%) | 3.00% | (87.24%) | (25.39%) | 23.44% | 13.30% |
Accounts Receivable Turnover |
0.00 | 0.00 | 20.80 | 8.36 | 8.33 | 9.49 | 4.31 | 3.30 | 4.97 | 6.30 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.06 | 0.17 | 0.23 | 0.29 | 0.13 | 0.48 | 3.56 | 3.73 |
Inventory Turnover |
— | — | 0.26 | 0.81 | 0.60 | 0.26 | 0.22 | 0.97 | 3.24 | 2.24 |
Average Days of Payables |
0.00 | 0.00 | 8,127.93 | 1,672.72 | 1,511.79 | 1,279.02 | 4,697.21 | 366.64 | 65.36 | 133.77 |
Days of Inventory on Hand |
— | — | 1,136.97 | 545.49 | 668.01 | 2,229.77 | 1,902.84 | 283.48 | 117.48 | 214.04 |
Average Receivables |
— | — | 2.14 | 7.09 | 13.04 | 15.72 | 27.90 | 35.44 | 36.08 | 46.69 |
Average Payables |
4.16 | 4.10 | 4.51 | 5.27 | 3.93 | 3.75 | 13.15 | 14.83 | 5.24 | 5.27 |
Average Inventory |
— | — | 1.12 | 1.12 | 1.50 | 4.13 | 7.87 | 7.32 | 5.76 | 8.75 |
Average Assets |
104.94 | 98.62 | 129.11 | 143.34 | 128.97 | 138.85 | 150.80 | 125.75 | 140.60 | 338.79 |
Average Common Equity |
73.20 | 77.84 | 105.26 | 81.85 | 43.92 | 32.20 | 8.38 | (21.13) | (12.68) | 197.38 |
Columns are period end dates